Summary The effect of adriamycin on human and mouse CFUGM was examined at concentrations and times suggested by plasma clearance data derived from the results of a number of published studies. Our results suggest that the high concentrations of drug present in the plasma for short periods of time following infusion are only weakly cytotoxic towards the CFUGM when incubated for similar times. In contrast, there was a considerably greater cytotoxic effect when the drug was examined at low concentrations for periods similar to those described for the terminal phase of adriamycin clearance. The principal metabolite, adriamycinol, was poorly cytotoxic.
Adriamycin has found widespread application in the treatment of many malignant disorders including solid tumours, leukaemias and lymphomas. It has made a significant contribution to the treatment of acute myeloid leukaemia, given as a repeated intravenous dose of 30-90 mg m 2 according to the schedule used. There is a cumulative cardiotoxic effect in about one third of patients at 550mgm2, increasing at higher doses and undoubtedly, this has limited the usefulness of the drug. To attempt to lessen or overcome this problem, a number of related anthracycline derivatives are now undergoing appraisal (Arcamone et al., 1979) . In addition, and because the cardiotoxic effect may be related to the initial plasma concentration of the drug, several centres have used different dose regimens based on critical pharmacokinetic analysis (Legha et al., 1982) . The relationship between the plasma concentration and the cytotoxicity of the drug is important and the present paper attempts to examine this problem by studying the effect of adriamycin at plasma concentrations on the bone marrow CFUGM population.
Based on detailed pharmacokinetic data (Ehninger et al., 1980; Robert et al., 1982 and Greene et al., 1983) , we have examined the effect of relatively high concentrations during short-term pulse experiments and low concentrations during long-term incubations. In the latter experiments, it was necessary to incorporate the drug into the CFUGM assay system during the 7-day incubation period.
Early studies (Takanashi & Bachur, 1976) metabolised to produce a wide range of compounds. However, subsequent work has shown that most of these apparent metabolites were artefactually produced during the analytical procedure. Recent studies (Peterson & Paul, 1982; Greene et al., 1983; Robert et al., 1982) have demonstrated that only one metabolite, adriamycinol, was present in the plasma, although the aglycone has also been detected (Ehninger et al., 1980) . We have therefore examined the effect of adriamycinol during the long-term experiments and also the effect of adriamycin aglycone, although the role of this compound as a metabolite is questionable. Also as an important comparison, we have examined these effects on the murine CFUGM population.
Materials and methods

Bone marrow
Bone marrow was obtained from ribs resected from haematologically normal patients undergoing thoracic surgery. In all instances, CFUGM growth was within normal limits. Bone marrow was obtained from the rib by cutting 2cm sections which were then gently compressed to force out the marrow. The marrow was collected into culture medium and the particles dispersed by passage through a 19G hypodermic syringe needle. The resulting suspension was allowed to stand for about ten minutes before the fat layer was removed. On the basis of the number of mature blood cells present, the preparation was essentially free from peripheral blood contamination.
Human CFUGM assay
Bone marrow cells were cultured in duplicate in 35 mm petri dishes at a concentration of 0.2 x 106 ml-1 in a 1 ml volume of a-medium containing nucleosides and nucleotides (Gibco Europe Ltd.), 15% v/v newborn calf serum (Gibco, Special Bobby Calf Serum) and 0.3% agar. Colony stimulating factor was provided as human placenta conditioned medium (Burgess et al., 1977) Mouse CFUGM assay Mice used in these experiments were randomly bred TO strain mice of both sexes. Bone marrow was obtained by gently flushing the lumen of the femurs with culture medium. Cells were used without further preparation after appropriate dilution. Cells at a concentration of 0.2 x 1Q6Mml1 were cultured in a-medium containing 5% v/v newborn calf serum and 15% donor horse serum (Gibco). Mouse heart conditioned medium was used as a source of colony stimulating factor (Byrne et al., 1978) .
Incubation with adriamycin and derivatives Stock solutions were prepared immediately prior to use. Solutions of adriamycin and adriamycinol were prepared in water and adriamycin aglycone in dimethyl sulphoxide. These solutions were diluted for use with culture medium.
For the short-term pulse experiments, the bone marrow cells were incubated in suspension culture usually at a concentration of 106 ml1 with a range of drug concentrations. After incubation, the reaction was stopped by diluting the cells with phosphate buffered saline and after washing the cells the CFUGM recovery was determined.
In the long-term experiments, the drugs were incorporated into the CFUGM assay system and therefore incubated for the seven day period only. Time (h) Figure 1 The effect of pulses of adriamycin on the growth of human bone marrow CFUGM at 2MM (0), and 1 MM (@) concentrations (Mean + s.e.). Figure 2 shows in one study (Greene et al., 1983) , following a 15 min infusion of 75 mg m -2, there was a rapid decline in concentration from 5 /uM to 0.1 1iM within 1h, but subsequent clearance was roughly log-linear and a concentration of lOnM was detected after 4 days. Results from other studies have been very similar and we feel confident in using these results in comparison with the results of our studies.
Long-term experiments
Because of the rapid changes in concentrations which are occurring in the plasma, particularly during the initial phase, the concentrations used in our experiments can only be a rough approximation to the in vivo conditions. The concentrations employed in the short-term experiments are adriamycin during these short time incubations is small.
Similar considerations also apply to the low concentration -long-term effect. As mentioned earlier, during these experiments it was necessary to incubate the drug during the course of the 7-day CFUGM assay period. Several studies have suggested that significant levels of adriamycin are present in the plasma at times approaching this period, (Rosso et al., 1972; Robert et al., 1983; Greene et al., 1983) . For example, in the latter study at three days post-infusion, plasma levels of adriamycin had fallen to 25nM and at this concentration 50% loss of CFUGM was observed in our assay system. Because of the roughly logarithmic decrease in the plasma concentration, the effective concentration prior to three days would be significantly higher. It would seem, therefore, that the cytotoxic effect of these low concentrations was considerably higher than that observed during the short-term high concentration exposures. These results are of interest in the light of pharmacokinetic data (Greene et al., 1983) , suggesting that the terminal phase of adriamycin clearance is responsible for 75% of the total drug exposure. Clearly, the concentrations found in the plasma during this phase are indeed cytotoxic and may well play the major part in the action of the drug.
Pharmacokinetic measurements show that adriamycinol is produced in quantatively significant amounts during the latter stages of clearance with concentrations approaching those of the parent drug. In our system, adriamycinol was markedly less cytotoxic than the parent drug with a 50% kill concentration of about 80nM, which is some 4-fold greater than for adriamycin. Similar results have been obtained in short-term experiments using a human ovarian cancer assay system (Ozols et al., 1980) . Evidence suggests that adriamycin aglycone is probably not a metabolite of adriamycin and is certainly not produced at significant levels. In our experiments, it was not cytotoxic against the human or mouse colony forming system. Undoubtedly, our results can only be taken as an approximation to the effectiveness of the drug in vivo. A better indication of its therapeutic effect might be obtained from its relative action on the pluripotent stem cell population (for which, of course, there is no human assay) and the malignant cell population, for which again in the case of many of the haematological malignancies, we do not have adequate assay systems. However, we feel that our results show that very low concentrations of adriamycin are cytotoxic, at least towards the CFUGM population. It is likely that the effectiveness of these concentrations is a function in part of the high affinity which most cells have towards adriamycin and there is no reason to suppose that other progenitor cells do not have a similar affinity for the drug.
It has been suggested on pharmacokinetic (Greene et al., 1983) and clinical grounds (Creasy et al., 1976; Legha et al., 1982) that the anti-tumour effect of adriamycin is dependent on the total dose and independent of the programme by which it is given, whereas the adverse side-effect and in particular, cardiotoxicity, is a feature of the peak drug concentrations. Our results prompt us to suggest that the adverse side-effects of these peak drug concentrations might be avoided if adriamycin was used at much lower dosage.
